5-Hydroxyindirubin targets FLT3 signaling and synergizes with venetoclax in FLT3-ITD acute myeloid leukemia
Authors:
- Yanshun DengYDYanshun Deng
- Chenghua XuCXChenghua Xu
- Bingqian ChuBCBingqian Chu
- Jinting FanJFJinting Fan
- Ning WangNWNing Wang
- Yang YangYYYang Yang
- Peiyuan YangPYPeiyuan Yang
- Youyang FangYFYouyang Fang
- Lichun KangLKLichun Kang
- Mingming NiuMNMingming Niu
- Xiaoxiao HuangXHXiaoxiao Huang
- Guodong YaoGYGuodong Yao
Open Access
- 1 March 2026
- journal article
- Published by KEAI Publishing in Fundamental Research
Abstract
No abstract availableFunding Information
- Natural Science Foundation of Tianjin Municipality (22JCJQJC00090)
- Sichuan Provincial Science and Technology Support Program (2023-QNRC2-B24)
- Sichuan Provincial Science and Technology Support Program (2025ZNSFSC0737)
- National Natural Science Foundation of China (82400271)
- National Natural Science Foundation of China (82403710)
- National Natural Science Foundation of China (82270236)
- National Natural Science Foundation of China (82341080)
- National Natural Science Foundation of China (82273217)
- Chinese Academy of Medical Sciences (2025-I2M-XHXX-134)
- Chinese Academy of Medical Sciences (2025-I2M-XHJC-037)
- Chinese Academy of Medical Sciences (2023-I2M-3-014)
- Chinese Academy of Medical Sciences (2023-I2M-2-007)
- Chinese Academy of Medical Sciences (2025-I2M-XHXX-135)
This publication has 27 references indexed in Scilit:
- Phosphatase Dysregulation in Cancer: Signaling Pathways and Therapeutic OpportunitiesMedComm – Oncology, 2025
- Long‐term follow‐up of VIALE‐A: Venetoclax and azacitidine in chemotherapy‐ineligible untreated acute myeloid leukemiaAmerican Journal of Hematology, 2024
- PLM-101 is a novel and potent FLT3/RET inhibitor with less adverse effects in the treatment of acute myeloid leukemiaBiomedicine & Pharmacotherapy, 2023
- Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2023
- Understanding gilteritinib resistance to FLT3-F691L mutation through an integrated computational strategyJournal of Molecular Modeling, 2022
- Pharmacological properties of indirubin and its derivativesBiomedicine & Pharmacotherapy, 2022
- Pharmacophore-inspired discovery of FLT3 inhibitor from kimchiFood Chemistry, 2021
- Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approachCancer, 2021
- Natural small molecule triptonide inhibits lethal acute myeloid leukemia with FLT3-ITD mutation by targeting Hedgehog/FLT3 signalingBiomedicine & Pharmacotherapy, 2021
- Identification of a Water-Soluble Indirubin Derivative as Potent Inhibitor of Insulin-like Growth Factor 1 Receptor through Structural Modification of the Parent Natural MoleculeJournal of Medicinal Chemistry, 2017